6.
Vega A, Torres M, Martinez J, Ruiz-Ponte C, Barros F, Carracedo A
. Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula. Ann Hum Genet. 2002; 66(Pt 1):29-36.
DOI: 10.1017/S0003480001001014.
View
7.
Veitia R
. Primary ovarian insufficiency, meiosis and DNA repair. Biomed J. 2020; 43(2):115-123.
PMC: 7283561.
DOI: 10.1016/j.bj.2020.03.005.
View
8.
Hohenstein P, Kielman M, Breukel C, Bennett L, Wiseman R, Krimpenfort P
. A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene. 2001; 20(20):2544-50.
DOI: 10.1038/sj.onc.1204363.
View
9.
Gowen L, Johnson B, Latour A, Sulik K, Koller B
. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet. 1996; 12(2):191-4.
DOI: 10.1038/ng0296-191.
View
10.
Chirita-Emandi A, Andreescu N, Popa C, Mihailescu A, Riza A, Plesea R
. Biallelic variants in gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency. J Med Genet. 2020; 58(9):648-652.
PMC: 8394758.
DOI: 10.1136/jmedgenet-2020-107198.
View
11.
Qin Y, Zhang F, Chen Z
. BRCA2 in Ovarian Development and Function. N Engl J Med. 2019; 380(11):1086.
DOI: 10.1056/NEJMc1813800.
View
12.
Walsh M, Chang V, Kohlmann W, Scott H, Cunniff C, Bourdeaut F
. Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clin Cancer Res. 2017; 23(11):e23-e31.
PMC: 5697784.
DOI: 10.1158/1078-0432.CCR-17-0465.
View
13.
Keupp K, Hampp S, Hubbel A, Maringa M, Kostezka S, Rhiem K
. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility. Mol Genet Genomic Med. 2019; 7(9):e863.
PMC: 6732317.
DOI: 10.1002/mgg3.863.
View
14.
Lord C, Ashworth A
. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158.
PMC: 6175050.
DOI: 10.1126/science.aam7344.
View
15.
Oostra A, Nieuwint A, Joenje H, de Winter J
. Diagnosis of fanconi anemia: chromosomal breakage analysis. Anemia. 2012; 2012:238731.
PMC: 3368163.
DOI: 10.1155/2012/238731.
View
16.
Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B
. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016; 31(5):926-37.
DOI: 10.1093/humrep/dew027.
View
17.
Fouquet B, Pawlikowska P, Caburet S, Guigon C, Makinen M, Tanner L
. A homozygous mutation underlies a familial case of non-syndromic primary ovarian insufficiency. Elife. 2017; 6.
PMC: 5764568.
DOI: 10.7554/eLife.30490.
View
18.
Alter B, Rosenberg P, Brody L
. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet. 2006; 44(1):1-9.
PMC: 2597904.
DOI: 10.1136/jmg.2006.043257.
View
19.
Helbling-Leclerc A, Garcin C, Rosselli F
. Beyond DNA repair and chromosome instability-Fanconi anaemia as a cellular senescence-associated syndrome. Cell Death Differ. 2021; 28(4):1159-1173.
PMC: 8026967.
DOI: 10.1038/s41418-021-00764-5.
View
20.
Bidet M, Bachelot A, Bissauge E, Golmard J, Gricourt S, Dulon J
. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. 2011; 96(12):3864-72.
DOI: 10.1210/jc.2011-1038.
View